A Study Measuring the Effectiveness, Safety, and Tolerability of BMS-986278 in Participants With Lung Fibrosis
Trial Summary
What is the purpose of this trial?
This trial is testing a new drug called BMS-986278 to help people with lung fibrosis. The goal is to see if it can reduce lung scarring and improve breathing. The study will also check if the drug is safe and how much of it stays in the body.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
Research Team
Bristol-Myers Squibb
Principal Investigator
Bristol-Myers Squibb
Eligibility Criteria
Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive BMS-986278 or placebo for the treatment of pulmonary fibrosis
Follow-up
Participants are monitored for safety and effectiveness after treatment
Optional Treatment Extension (OTE)
Participants may opt into continuation of treatment long-term
Treatment Details
Interventions
- BMS-986278
- BMS-986278 Placebo
BMS-986278 is already approved in United States for the following indications:
- Progressive Pulmonary Fibrosis (Breakthrough Therapy Designation)
Find a Clinic Near You
Who Is Running the Clinical Trial?
Bristol-Myers Squibb
Lead Sponsor
Christopher Boerner
Bristol-Myers Squibb
Chief Executive Officer since 2023
PhD in Business Administration from the Haas School of Business, University of California, Berkeley; BA in Economics and History from Washington University in St. Louis
Deepak L. Bhatt
Bristol-Myers Squibb
Chief Medical Officer since 2024
MD from Yale University; MSc in Clinical Epidemiology from the University of Pennsylvania